KPV is a tripeptide fragment of alpha-MSH studied in anti-inflammatory and gut research. Patients can request a telehealth evaluation through the TelosRX Telehealth Portal to discuss compounded access.
What Is KPV?
KPV (Lysine-Proline-Valine) is a 3-amino-acid peptide derived from alpha-melanocyte-stimulating hormone. It is studied in preclinical research for inflammation pathways.
KPV is not an FDA-approved drug. It is available through compounding pharmacies under valid prescription.
Common Discussion Points
Patients often raise KPV during evaluations for:
- Inflammatory pathway research interest
- Gut health discussions
- Skin and tissue research
- Recovery research applications
A licensed provider determines clinical appropriateness individually.
2026 Regulatory Context
In July 2026, an FDA advisory committee voted to recommend adding KPV to the list of bulk substances for compounding; the vote was non-binding. On October 28, 2026, HHS announced a temporary enforcement discretion policy covering compounded KPV in topical and oral forms only (not injection), under strict conditions, while FDA finishes rulemaking. It is not FDA approval. Patients interested in compounded access should consult a licensed provider.
How TelosRX Handles KPV
TelosRX is an online-first telehealth service. Patient evaluation is asynchronous, and compounded medications are prepared through our licensed pharmacy partner.
- Step 1: Complete an asynchronous telehealth intake at TelosRX.
- Step 2: Licensed provider review.
- Step 3: Prescription issued if clinically appropriate.
- Step 4: Compounded KPV ships discreetly to your door.
Important Compliance Information
KPV is not FDA-approved. Compounded preparations are prepared under federal compounding regulations.
Prescriptions require evaluation by a licensed healthcare provider. Approval is not guaranteed. Individual results vary.
TelosRX operates under LegitScript-certified telehealth standards.
Start your private evaluation at TelosRX.